Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Shares Outstanding (Diluted Average): 2021-2025

Historic Shares Outstanding (Diluted Average) for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $62.0 million.

  • Janux Therapeutics' Shares Outstanding (Diluted Average) rose 13.54% to $62.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.0 million, marking a year-over-year increase of 13.54%. This contributed to the annual value of $53.8 million for FY2024, which is 22.12% up from last year.
  • Janux Therapeutics' Shares Outstanding (Diluted Average) amounted to $62.0 million in Q3 2025, which was up 0.20% from $61.9 million recorded in Q2 2025.
  • Janux Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $62.0 million during Q3 2025, with a 5-year trough of $10.0 million in Q2 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $53.8 million (2024), whereas its average is $51.9 million.
  • Data for Janux Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 313.11% (in 2022) over the last 5 years.
  • Over the past 5 years, Janux Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $23.5 million in 2021, then skyrocketed by 76.24% to $41.5 million in 2022, then climbed by 6.14% to $44.0 million in 2023, then climbed by 22.12% to $53.8 million in 2024, then grew by 13.54% to $62.0 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $62.0 million for Q3 2025, versus $61.9 million for Q2 2025 and $61.8 million for Q1 2025.